User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.

Primary tabs

Grom, Alexei A Ilowite, Norman T Pascual, Virginia Brunner, Hermine I Martini, Alberto Lauwerys, Bernard [UCL]

(eng) OBJECTIVE: In pivotal trials, canakinumab has been shown to be effective in the treatment of systemic juvenile idiopathic arthritis (JIA), but reported adverse events have included macrophage activation syndrome (MAS). This study was undertaken to assess the impact of canakinumab on MAS incidence. METHODS: An independent MAS Adjudication Committee (MASAC), consisting of 3 of the authors, was convened, and a search of databases from clinical studies of canakinumab treatment in systemic JIA was performed using MASAC-specified adverse event terms to identify potential MAS events. These were then adjudicated as "probable MAS," "possible MAS," or "MAS unlikely," using criteria developed by the MASAC. MAS rates were expressed as numbers of cases per 100 patient-years. RESULTS: Of 72 potential MAS cases identified, 21 events (19 with canakinumab treatment; 2 with placebo treatment) in 19 patients were adjudicated as being probable MAS and 10 events in 9 patients as being possible MAS. Systemic JIA was well controlled in the majority of canakinumab-treated patients at the time of MAS. The time period between initiation of canakinumab treatment and onset of MAS ranged from 3 to 1,358 days (median 292 days). When the rates of probable MAS events were compared between canakinumab-treated patients (2.8 per 100 patient-years) and placebo-treated patients (7.7 per 100 patient-years), the difference was not significant (-4.9 [95% confidence interval -15.6, 5.9]). There were 3 deaths due to MAS-related complications (2 in patients receiving canakinumab; 1 in a patient receiving placebo); full recovery was reported in all other patients. Infections were the most common trigger of MAS, and the clinical features of MAS were not modified by canakinumab. CONCLUSION: Canakinumab does not have a significant effect on MAS risk or its clinical features in patients with systemic JIA. Infections are the most common trigger, and MAS occurs even in patients whose systemic JIA is well controlled with this treatment. TRIAL REGISTRATION: ClinicalTrials.gov NCT00886769 NCT00889863 NCT00891046.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2016
Language Anglais
Journal information "Arthritis & Rheumatology" - Vol. 68, no. 1, p. 218-228 (2016)
Peer reviewed yes
Publisher John Wiley & Sons, Inc. ((United States) Malden, MA)
issn 2326-5191
e-issn 2326-5205
Publication status Publié
Affiliations UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales
UCL - (SLuc) Service de rhumatologie
Links
  1. Schneider Rayfel, Laxer Ronald M., 6 Systemic onset juvenile rheumatoid arthritis, 10.1016/s0950-3579(98)80018-6
  2. Petty, J Rheumatol, 25, 1991 (1998)
  3. Mellins Elizabeth D., Macaubas Claudia, Grom Alexei A., Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions, 10.1038/nrrheum.2011.68
  4. Verbsky, J Rheumatol, 31, 2071 (2004)
  5. Irigoyen, Arthritis Rheum, 50, S437 (2004)
  6. Pascual Virginia, Allantaz Florence, Arce Edsel, Punaro Marilynn, Banchereau Jacques, Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade, 10.1084/jem.20050473
  7. Benedetti, J Rheumatol, 25, 203 (1998)
  8. Hadchouel Michelle, Prieur Anne-Marie, Griscelli Claude, Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: Possible relationship to drugs or infection, 10.1016/s0022-3476(85)80072-x
  9. Grom Alexei A., Natural killer cell dysfunction: A common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?, 10.1002/art.20198
  10. Sawhney S, Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders, 10.1136/adc.85.5.421
  11. Moradinejad, Minerva Pediatr, 63, 459 (2011)
  12. Bleesing Jack, Prada Anne, Siegel David M., Villanueva Joyce, Olson Judyann, Ilowite Norman T., Brunner Hermine I., Griffin Thomas, Graham Thomas B., Sherry David D., Passo Murray H., Ramanan Athimalaipet V., Filipovich Alexandra, Grom Alexei A., The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor α-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis, 10.1002/art.22416
  13. Behrens, J Rheumatol, 34, 1133 (2007)
  14. Athreya, Clin Exp Rheumatol, 20, 121 (2002)
  15. Filipovich Alexandra H, Hemophagocytic lymphohistiocytosis, 10.1016/s0889-8561(01)00009-1
  16. Henter, Blood, 78, 2918 (1991)
  17. Henter Jan-Inge, Andersson Birger, Elinder Göran, Jakobson Åke, Lübeck Per-Olof, Söder Olle, Elevated circulating levels of interleukin-1 receptor antagonist but not IL-1 agonists in hemophagocytic lymphohistiocytosis, 10.1002/(sici)1096-911x(199607)27:1<21::aid-mpo5>3.0.co;2-w
  18. Ravelli Angelo, De Benedetti Fabrizio, Viola Stefania, Martini Alberto, Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine, 10.1016/s0022-3476(96)70408-0
  19. Stephan J. L., Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients, 10.1093/rheumatology/40.11.1285
  20. Henter Jan-Inge, Horne AnnaCarin, Aricó Maurizio, Egeler R. Maarten, Filipovich Alexandra H., Imashuku Shinsaku, Ladisch Stephan, McClain Ken, Webb David, Winiarski Jacek, Janka Gritta, , HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis, 10.1002/pbc.21039
  21. Coca Andreea, Bundy Kemp W., Marston Bethany, Huggins Jennifer, Looney R. John, Macrophage activation syndrome: Serological markers and treatment with anti-thymocyte globulin, 10.1016/j.clim.2009.02.005
  22. Schulert Grant S., Grom Alexei A., Macrophage activation syndrome and cytokine-directed therapies, 10.1016/j.berh.2014.03.002
  23. Quartier P., Allantaz F., Cimaz R., Pillet P., Messiaen C., Bardin C., Bossuyt X., Boutten A., Bienvenu J., Duquesne A., Richer O., Chaussabel D., Mogenet A., Banchereau J., Treluyer J.-M., Landais P., Pascual V., A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial), 10.1136/ard.2010.134254
  24. Ruperto Nicolino, Brunner Hermine I., Quartier Pierre, Constantin Tamás, Wulffraat Nico, Horneff Gerd, Brik Riva, McCann Liza, Kasapcopur Ozgur, Rutkowska-Sak Lidia, Schneider Rayfel, Berkun Yackov, Calvo Inmaculada, Erguven Muferet, Goffin Laurence, Hofer Michael, Kallinich Tilmann, Oliveira Sheila K., Uziel Yosef, Viola Stefania, Nistala Kiran, Wouters Carine, Cimaz Rolando, Ferrandiz Manuel A., Flato Berit, Gamir Maria Luz, Kone-Paut Isabelle, Grom Alexei, Magnusson Bo, Ozen Seza, Sztajnbok Flavio, Lheritier Karine, Abrams Ken, Kim Dennis, Martini Alberto, Lovell Daniel J., Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis, 10.1056/nejmoa1205099
  25. Yokota Shumpei, Imagawa Tomoyuki, Mori Masaaki, Miyamae Takako, Aihara Yukoh, Takei Shuji, Iwata Naomi, Umebayashi Hiroaki, Murata Takuji, Miyoshi Mari, Tomiita Minako, Nishimoto Norihiro, Kishimoto Tadamitsu, Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial, 10.1016/s0140-6736(08)60454-7
  26. De Benedetti Fabrizio, Brunner Hermine I., Ruperto Nicolino, Kenwright Andrew, Wright Stephen, Calvo Inmaculada, Cuttica Ruben, Ravelli Angelo, Schneider Rayfel, Woo Patricia, Wouters Carine, Xavier Ricardo, Zemel Lawrence, Baildam Eileen, Burgos-Vargas Ruben, Dolezalova Pavla, Garay Stella M., Merino Rosa, Joos Rik, Grom Alexei, Wulffraat Nico, Zuber Zbigniew, Zulian Francesco, Lovell Daniel, Martini Alberto, Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis, 10.1056/nejmoa1112802
  27. KAHN P. J., CRON R. Q., Higher-dose Anakinra Is Effective in a Case of Medically Refractory Macrophage Activation Syndrome, 10.3899/jrheum.121098
  28. Miettunen P. M., Narendran A., Jayanthan A., Behrens E. M., Cron R. Q., Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients, 10.1093/rheumatology/keq218
  29. Zeft Andrew, Hollister Roger, LaFleur Bonnie, Sampath Prahalad, Soep Jennifer, McNally Bernadette, Kunkel Gary, Schlesinger Margaret, Bohnsack John, Anakinra for Systemic Juvenile Arthritis : The Rocky Mountain Experience, 10.1097/rhu.0b013e3181a4f459
  30. Nigrovic Peter A., Mannion Melissa, Prince Femke H. M., Zeft Andrew, Rabinovich C. Egla, van Rossum Marion A. J., Cortis Elisabetta, Pardeo Manuela, Miettunen Paivi M., Janow Ginger, Birmingham James, Eggebeen Aaron, Janssen Erin, Shulman Andrew I., Son Mary Beth, Hong Sandy, Jones Karla, Ilowite Norman T., Cron Randy Q., Higgins Gloria C., Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series, 10.1002/art.30128
  31. Billiau A. D., Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN- -producing lymphocytes and IL-6- and TNF- -producing macrophages, 10.1182/blood-2004-08-2997
  32. Strippoli Raffaele, Carvello Francesco, Scianaro Roberta, De Pasquale Loredana, Vivarelli Marina, Petrini Stefania, Bracci-Laudiero Luisa, De Benedetti Fabrizio, Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: Implication for the pathogenesis of macrophage activation syndrome, 10.1002/art.33496
  33. Ruperto Nicolino, Quartier Pierre, Wulffraat Nico, Woo Patricia, Ravelli Angelo, Mouy Richard, Bader-Meunier Brigitte, Vastert Sebastiaan J., Noseda Emanuele, D'Ambrosio Daniele, Lecot Jean, Chakraborty Abhijit, Martini Alberto, Chioato Andrea, , A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features, 10.1002/art.33342
  34. Giannini Edward H., Ruperto Nicolino, Ravelli Angelo, Lovell Daniel J., Felson David T., Martini Alberto, Preliminary definition of improvement in juvenile arthritis, 10.1002/1529-0131(199707)40:7<1202::aid-art3>3.0.co;2-r
  35. Ravelli Angelo, Magni-Manzoni Silvia, Pistorio Angela, Besana Cristina, Foti Tiziana, Ruperto Nicolino, Viola Stefania, Martini Alberto, Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis, 10.1016/j.jpeds.2004.12.016
  36. DAVI S., CONSOLARO A., GUSEINOVA D., PISTORIO A., RUPERTO N., MARTINI A., CRON R. Q., RAVELLI A., , An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis, 10.3899/jrheum.100996
  37. Ringold Sarah, Weiss Pamela F., Beukelman Timothy, DeWitt Esi Morgan, Ilowite Norman T., Kimura Yukiko, Laxer Ronald M., Lovell Daniel J., Nigrovic Peter A., Robinson Angela Byun, Vehe Richard K., 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among C : ACR 2013 Updated Recommendations for the Medical Treatment of JIA, 10.1002/art.38092
  38. Ringold Sarah, Weiss Pamela F., Beukelman Timothy, DeWitt Esi Morgan, Ilowite Norman T., Kimura Yukiko, Laxer Ronald M., Lovell Daniel J., Nigrovic Peter A., Robinson Angela Byun, Vehe Richard K., 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among C : ACR 2013 Updated Recommendations for the Medical Therapy of JIA, 10.1002/acr.22087
  39. Schulert Grant S., Grom Alexei A., Pathogenesis of Macrophage Activation Syndrome and Potential for Cytokine- Directed Therapies, 10.1146/annurev-med-061813-012806
  40. De Benedetti Fabrizio, Schneider Rayfel, Weitzman Sheila, Devlin Clare, Daimaru Kaori, Yokota Shumpei, Takei Syuji, Ravelli Angelo, Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab, 10.1186/1546-0096-12-s1-p55
  41. Kobayashi Masafumi, Takahashi Yuko, Yamashita Hiroyuki, Kaneko Hiroshi, Mimori Akio, Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome, 10.3109/s10165-010-0348-9
  42. Shimizu Masaki, Nakagishi Yasuo, Kasai Kazuko, Yamasaki Yuichi, Miyoshi Mari, Takei Syuji, Yachie Akihiro, Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The diagnostic significance of interleukin-18 and interleukin-6, 10.1016/j.cyto.2012.02.006
  43. Shimizu M., Yokoyama T., Yamada K., Kaneda H., Wada H., Wada T., Toma T., Ohta K., Kasahara Y., Yachie A., Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis, 10.1093/rheumatology/keq133
  44. Maeno Nobuaki, Takei Syuji, Imanaka Hiroyuki, Yamamoto Kimie, Kuriwaki Kazumi, Kawano Yoshifumi, Oda Hiroshi, Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome, 10.1002/art.20268
  45. Dinarello Charles A., Interleukin-18 and the Pathogenesis of Inflammatory Diseases, 10.1016/j.semnephrol.2006.09.013
  46. Mazodier K., Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome, 10.1182/blood-2005-05-1980
  47. Canna Scott W., Wrobel Julia, Chu Niansheng, Kreiger Portia A., Paessler Michele, Behrens Edward M., Interferon-γ Mediates Anemia but Is Dispensable for Fulminant Toll-like Receptor 9-Induced Macrophage Activation Syndrome and Hemophagocytosis in Mice : IFN-γ-Independent MAS and Hemophagocytosis, 10.1002/art.37958
  48. Jordan M. B., An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder, 10.1182/blood-2003-10-3413
  49. Put Karen, Avau Anneleen, Brisse Ellen, Mitera Tania, Put Stéphanie, Proost Paul, Bader-Meunier Brigitte, Westhovens René, Van den Eynde Benoit J., Orabona Ciriana, Fallarino Francesca, De Somer Lien, Tousseyn Thomas, Quartier Pierre, Wouters Carine, Matthys Patrick, Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ, 10.1093/rheumatology/keu524
  50. Bracaglia Claudia, Caiello Ivan, De Graaf Kathy, D'Ario Giovanni, Guilhot Florence, Ferlin Walter, Melli Lidia, Prencipe Giusi, Davì Sergio, Schulert Grant, Ravelli Angelo, Grom Alexei, De Min Cristina, De Benedetti Fabrizio, Interferon-gamma (IFNy) in macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA). High levels in patients and a role in a murine mas model, 10.1186/1546-0096-12-s1-o3
  51. Zhang K., Jordan M. B., Marsh R. A., Johnson J. A., Kissell D., Meller J., Villanueva J., Risma K. A., Wei Q., Klein P. S., Filipovich A. H., Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH, 10.1182/blood-2011-07-370148
  52. Vastert Sebastiaan J., van Wijk Richard, D’Urbano Leila E., de Vooght Karen M. K., de Jager Wilco, Ravelli Angelo, Magni-Manzoni Silvia, Insalaco Antonella, Cortis Elisabetta, van Solinge Wouter W., Prakken Berent J., Wulffraat Nico M., de Benedetti Fabrizio, Kuis Wietse, Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis, 10.1093/rheumatology/kep418
  53. Zhang Mingce, Behrens Edward M., Atkinson T. Prescott, Shakoory Bita, Grom Alexei A., Cron Randy Q., Genetic Defects in Cytolysis in Macrophage Activation Syndrome, 10.1007/s11926-014-0439-2
  54. Kaufman, Rheumatol, 66, 3486 (2014)
Bibliographic reference Grom, Alexei A ; Ilowite, Norman T ; Pascual, Virginia ; Brunner, Hermine I ; Martini, Alberto ; et. al. Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.. In: Arthritis & Rheumatology, Vol. 68, no. 1, p. 218-228 (2016)
Permanent URL http://hdl.handle.net/2078.1/172388